A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety

International Journal of Psychiatry in Clinical Practice

Volumn 8, Issue 4, 2004, Pages 205-211

  Ilhan Yargic, L ^a   Corapcioglu, Aytul ^b,c   Kocabasoglu, Nese ^a   Erdogan, Ayten ^a   Koroglu, Gulsah ^b   Yilmaz, Dilek ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b KOCAELI UNIVERSITY   (Turkey)

^c Cerrahpasa School of Medicine ^*  (Turkey)

Author keywords

Anxiety; Atypical antipsychotic; Depression; Paroxetine; Quetiapine

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; PAROXETINE; QUETIAPINE;

ADULT; AGED; AGITATION; AMENORRHEA; ANXIETY; ANXIETY DISORDER; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPEPSIA; FEMALE; FLATULENCE; HEADACHE; HUMAN; HYPERHIDROSIS; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREMOR; VERTIGO; VISUAL DISORDER; XEROSTOMIA;

EID: 10044241632     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500410005720     Document Type: Article

References (25)

1. Arean PA, Alvidrez J (2001) Treating depressive disorders: who responds, who does not respond, and who do we need to study? J Fam Pract 50: E2.
2. Marangell LB (2001) Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry 62 (Suppl 18): 12-7.
3. Gorman JM (1996) Comorbid depression and anxiety spectrum disorders. Depress Anxiety 4: 160-8.
4. Gorman JM, Papp LA (2000) Efficacy of venlafaxine in mixed depression-anxiety states. Depress Anxiety 12 (Suppl 1): 77-80.
5. Rouillon F (1999) Anxiety with depression: a treatment need. Eur Neuropsychopharmacol 9 (Suppl 3): 87-92.
6. Kuzel RJ (1996) Treating comorbid depression and anxiety. J Fam Pract 43 (Suppl 6): 45-53.
7. Nutt DJ (1999) Care of depressed patients with anxiety symptoms. J Clin Psychiatry 60 (Suppl 17): 23-7.
8. Lader MH (1999) Limitations on the use of benzodiazepines in anxiety and insomnia: Are they justified? Eur Neuropsychopharmacol 6: 399-405.
9. Glick ID, Murray SR, Vasudevan P et al (2001) Treatment with atypical antipsychotics: New indications and new populations. J Psychiatr Res 35: 187-91.
10. Weizman R, Weizman A (2001) Use of atypical antipsychotics in mood disorders. Curr Opin Invest Drug 2: 940-5.
11. Keck PE, Strakowski SM, McElroy SL (2000) The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 61 (Suppl 3): 4-9.
12. Devane CL, Nemeroff CB (2001) Clinical pharmacokinetics of quetiapine: An atypical antipsychotic. Clin Pharmacokinet 40: 509-22.
13. Mullen J, Jibson MD, Sweitzer D (2001) A comparison of relative safety, efficacy and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: The quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23: 1839-54.
14. Sramek JJ, Tansman M, Suri A et al (1996) Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 57 (7): 287-91.
15. Fresquet A, Sust M, Lloret A et al (2000) Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder. Ann Pharmacother 34 (2): 147-53.
16. Mauri MC, Bitetto A, Fabiano L et al (1999) Depressive symptoms and schizophrenic relapses: the effect of four neuroleptic drugs. Prog Neuropsychopharmacol Biol Psychiatry 23: 43-54.
17. Tollefson GD, Sanger TM, Beasly CM et al (1998) A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 43: 803-10.
18. Muller-Siecheneder F, Muller MJ, Hillert A (1998) Risperidone versus haloperidol and amitryptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 18: 111-20.
19. Krakowski M, Czobor P, Volavka J (1997) Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Res 71 (1): 19-26.
20. Ostroff RB, Nelson JC (1999) Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 60: 256-9.
21. Hirose S, Ashby CR (2002) An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 63: 733-6.
22. Kaplan M (2000) Atypical antipsychotics for treatment of mixed depression and anxiety. J Clin Psychiatry 61: 388-9.
23. Hamilton M (1960) A rating scale for depression. J Neurology Neurosurgery Psychiatry 23: 56-62.
24. Nemeroff CB (1993) Paroxetine: an overview of the efficacy and safety of a new selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol 13 (Suppl 2): 10-7.
25. Nasrallah H (2003) A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28: 83-96.